Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : Botanical or Dissociative or Synthetic cannabinoid

Use the filters below to narrow your results.

generic:
brand:
None (48) · DXM (1) · DXO (1) · Spravato (1)
classes: (Click arrow to add another value)
mechanism:
CB1/CB2 agonist (7) · NMDA antagonist (3) · Contains LSA (2) · Contains mescaline (2) · NMDA antagonist; sigma receptor agonist (2)
uses:
None (50) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1)
starting dose:
None (50) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)
preparations:
None (50) · 28 mg/device (each dose uses 2 devices) (1)
fda max:
None (50) · 84 mg per session (1)
routes:
None (50) · Intranasal (under direct medical supervision) (1)
onset:
None (50) · Within hours of first administration (1)
duration:
None (50) · Acute effect ~24 hours; cumulative effect builds with repeated dosing (1)
halflife:
None (50) · ~7-12 hours (1)
bioavailability:
None (50) · ~48% intranasal (1)
pregnancy:
None (50) · Avoid; may cause fetal harm (1)
legal:
None (50) · Rx, Schedule III (US). REMS program required. (1)

Showing below up to 52 results in range #1 to #52.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"